Previous 10 | Next 10 |
2024-04-25 18:28:44 ET Summary Neurocrine Biosciences, Inc. achieved positive results achieved from phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with Major Depressive Disorder. NBI-1065845 may offer some advantages over currently approved MDD therapies, su...
2024-04-24 19:08:44 ET More on Neurocrine Biosciences Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript Neurocrine Biosciences upgraded at Wells Fargo on pipeline Neuro...
2024-04-24 15:15:12 ET Wells Fargo analyst issues OVERWEIGHT recommendation for NBIX on April 23, 2024 04:12PM ET. The previous analyst recommendation was Buy. NBIX was trading at $139.345 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-04-24 11:59:30 ET More on Neurocrine Biosciences Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript Neurocrine succeeds in mid-stage trial for Takeda-partnered depression d...
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community PR Newswire WHAT THE C@H?! provides a platform for the congenital adrenal hyperplasia (CAH) community to find educational information, share...
2024-04-23 14:22:14 ET More on Neurocrine Biosciences Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript Sentia Medical Sciences and Neurocrine Biosciences extend research colla...
2024-04-23 08:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder PR Newswire SAVITRI ™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale ( MA...
2024-04-16 16:09:56 ET More on Neurocrine Biosciences Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside Neurocrine Biosciences (NBIX) Q4 2023 Earnings Call Transcript Neurocrine Biosciences Q4 2023 Earnings Preview Seeking Alpha...
2024-04-15 06:38:19 ET More on smallcaps and midcaps IWM A Bargain As The S&P 500's P/E Hits 21x It's Selling Season For The Russell 2000 And ETFs That Track It IWM: Are Small Caps Being Overlooked In The Megacap Market Frenzy? Overbought conditions flash...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $170.00 for NBIX on 2024-07-12 08:10:00. The adjusted price target was set to $170.00. At the time of the announcement, NBIX was trading at $146.5. The overall price target consensus is at $...
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results PR Newswire Conference Call and Webcast Scheduled for Thursday, August 1 SAN DIEGO , July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasd...